ANTIBODIES AGAINST BENZO[A]PYRENE, ESTRADIOL AND PROGESTERONE MAY BE THE PREDICTORS OF BREAST CANCER PROGRESSION?



Cite item

Full Text

Abstract

Abstract

The aim of this study is to reveal the proposed associations of the serum IgA and IgG antibodies against Bp, E2 and Pg, as well as E2 and Pg, with expression of ER, PR and Ki-67 in tumor during BC progression. The content of these antibodies and hormones in the blood serum of BCP I stage (N = 721) and II–IV stages (N = 853) was studied using enzyme-linked immunosorbent assay. Tumor ER, PR and Ki-67 positive cells were detected using immunohistochemical methods. The percentage of BCP with high levels of Ki-67 positive tumor cells (>20%) at the II–IV stages was higher than at the I stage independently of IgA-Bp, IgA-E2 and IgA-Pg levels as well as individuals IgA-E2/IgA-Pg ratios (р<0.001).  Such increasing of Ki-67 positive tumors was statistically insignificant in BCP with low IgA-Bp/IgA-Pg ratio (<1, p = 0.07). Decreasing of ER+/PR+ and increasing of ER-/PR- tumors were insignificant in BCP with averad  levels of IgA-Bp (2–4 CU,  р = 0.07) and IgA-Pg (1–2 CU, p = 0.11) and low ratios of IgA-Bp/IgA-Pg<1 (p = 0.43) and IgA-E2/IgA-Pg<1(р = 0.99). Such ER+/PR+ transformation was statistically significant (p<0.01) in the all others cases. There were no any associations of ER, PR and Ki-67 tumor transformation with studied IgG antibodies. The percentage of BCP with high levels of Ki-67 positive cells in tumor was not increased when E2 serum concentration was low (<100 pMol/L, p = 0.11), and when Pg/E2 ratio was high (>6, р = 0.06). Increasing of ER-/PR- tumors proportion was insignificant in BCP with low Pg levels (<400 pMol/L, p = 0.24) and low Pg/E2 ratios <3 (р = 0.13). Immunoassay for IgA-Bp, IgA-E2 and IgA-Pg is proposed for assessing tumor progressing in BCP (rate of proliferation and steroid receptors inversion).

About the authors

Andrey N. Glushkov

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: glushkovan@ihe.sbras.ru
ORCID iD: 0000-0002-8560-6719
SPIN-code: 9536-8530
Scopus Author ID: 7006323832
ResearcherId: Q-5985-2016

PhD, MD (Medicine), Professor, Chief Research Associate, Laboratory of Immunogenetics

Russian Federation, 650065, Russia, Kemerovo, Leningradsky Avenue, 10

Elena G. Polenok

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: egpolenok@mail.ru
ORCID iD: 0000-0002-9368-2340
SPIN-code: 3925-0185
Scopus Author ID: 6506567994
ResearcherId: Q-5381-2016

PhD (Pharmacy), Leading Research Associate, Laboratory of Immunochemistry

Russian Federation, 650065, Russia, Kemerovo, Leningradsky Avenue, 10

Lyudmila A. Gordeeva

Federal Research Center of Coal and Coal chemistry SB RAS, Institute of Human Ecology, Kemerovo, Russian Federation

Email: gorsib@rambler.ru
ORCID iD: 0000-0001-5870-7584
SPIN-code: 6662-4616
Scopus Author ID: 14052058500
ResearcherId: R-2781-2016

PhD (Biology), Leading Research Associate, Laboratory of Immunogenetics

Russian Federation, 650065, Russia, Kemerovo, Leningradsky Avenue, 10

Mikhail V. Kostyanko

Kemerovo State University, Institute of Fundamental Sciences, Kemerovo, Russian Federation

Email: kmvksu@mail.ru
ORCID iD: 0000-0003-0053-1752
SPIN-code: 5953-6554
Scopus Author ID: 6507008191

Leading Engineer, Department of Organic Chemistry

Russian Federation, 650000, Russia, Kemerovo, Krasnaya Street, 6

Vadim N. Zakharov

Kuzbass Clinical Oncology Dispensary, Kemerovo, Russian Federation

Email: vadim-zaxarov2016@yandex.ru
ORCID iD: 0009-0003-1731-1534

PhD (Candidate of Medicine), Main Physician

Russian Federation, 650036, Russia, Kemerovo, Volgogradskaya Street, 35

Alexander V. Antonov

Kuzbass Clinical Oncology Dispensary, Kemerovo, Russian Federation

Email: al0412@mail.ru
ORCID iD: 0000-0003-0802-9759

Chief, Breast Cancer Department

Russian Federation, 650036, Russia, Kemerovo, Volgogradskaya Street, 35

Pavel V. Bairamov

Kuzbass Clinical Oncology Dispensary, Kemerovo, Russian Federation

Email: bayramov_pavel82@mail.ru
ORCID iD: 0000-0002-4649-5892

Head, Pathology Department

Russian Federation, 650036, Russia, Kemerovo, Volgogradskaya Street, 35

Natalia E. Verzhbitskaja

Kuzbass Clinical Oncology Dispensary, Kemerovo, Russian Federation

Email: verzhbitskaia@mail.ru
ORCID iD: 0000-0003-3860-825X

PhD (Medicine), Clinical Pathologist, Pathology Department

Russian Federation, 650036, Russia, Kemerovo, Volgogradskaya Street, 35

Gleb I. Kolpinskiy

Kemerovo State Medical University, Kemerovo, Russian Federation;
Kemerovo Clinical Diagnostic Сenter, Kemerovo, Russian Federation

Author for correspondence.
Email: Glebss@mail.ru
ORCID iD: 0000-0002-5526-2687
SPIN-code: 6894-6419
Scopus Author ID: 56677706300

PhD, MD (Medicine), Professor, Department of Radiology, Radiotherapy and Oncology; Main Physician

Russian Federation, 650056, Russia, Kemerovo, Voroshilov Street, 22A; 650066, Russia, Kemerovo, Oktyabrsky Avenue, 53/1

References

  1. Glushkov A.N., Polenok E.G., Mun S.A., Magarill Y.A., Gordeeva L.A., Lutsenko V.A., Kolpinskiy G.I., Kostyanko M.V., Vafin I.A. Effect of anti-antibodies to estradiol and progesterone on the concentration of hormones in the blood serum of healthy women and breast cancer patients. Siberian Journal of Oncology, 2020, Vol. 19, no. 2, pp. 62-69. [doi: 10.21294/1814-4861-2020-19-2-62-69]
  2. Ismagilov A.Kh., Vanesyan A.S., Khuzina D.R. Development of the predictive model for I stage breast cancer. Tumors of female reproductive system, 2021, Vol. 17 no. 2, pp. 14 22. (In Russ.) [doi: 10.17650/1994-4098-2021-17-2-14-22]
  3. Ismagilov A.Kh., Khuzina D.R., Vanesyan A.S., Zaysteva V.V. The role of biomarkers in the early diagnostics of breast cancer. Tumors of female reproductive system, 2020, Vol. 16, no. 4, pp. 35-40. (In Russ.) [doi: 10.17650/1994-4098-2020-16-4-35-40]
  4. Polenok E.G., Gordeeva L.A., Mun S.A., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.E., Bairamov P.V., Kolpinskiy G.I., Vafin I.A., Glushkov A.N. Cooperation of idiotypic and anti-idiotypic antibodies at the steroid-depended chemical carcinogenesis. Russian Journal of Immunology, 2023, Vol. 26, no. 1, pp. 27-40. (In Russ.) [doi: 10.46235/1028-7221-1177-COI]
  5. Polenok E.G., Mun S.A., Gordeeva L.A., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.E., Kolpinskiy G.I., Glushkov A.N. Associations of antibodies to benzo[a]pyrene, estradiol and progesterone with estrogen receptor phenotype in breast cancer tissue. Fundamental and Clinical Medicine, 2022, Vol.7, no. 1, pp. 53-63. (In Russ.) [doi: 10.23946/2500-0764-2022-7-1-53-63]
  6. Strunkin D.N., Kononchuk V.V., Gulyaeva L.F., Bogachev S.S., Proskurina A.S. Current aspects of systematics, diagnosis and treatment of breast cancer. Opuholi ženskoj reproduktivnoj sistemy = Tumors of female reproductive system, 2022, Vol. 18, no. 1, pp. 25-39. (In Russ.) [doi: 10.17650/1994-4098-2022-18-1-25-39]
  7. Altwegg K.A., Vadlamudi R.K. Role of estrogen receptor coregulators in endocrine resistant breast cancer. Explor. Target. Anti-tumor Ther., 2021, Vol. 2, no. 4, pp. 385-400. [doi: 10.37349/etat.2021.00052]
  8. Brown J., Scardo S., Method M., Schlauch D., Misch A., Picard S., Hamilton E., Jones S., Burris H., Spigel D.. A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2- early breast cancer in the United States. BMC Cancer, 2022, Vol. 22, no. 1, pp. 502. [doi: 10.1186/s12885-022-09557-6]
  9. Caldwell B.V., Tillson S.A., Esber H., Thorneycroft I.H. Survival of tumors after immunization against oestrogens. Nature, 1971, Vol. 231, no. 5298, pp. 118-119. [doi: 10.1038/231118a0]
  10. Dimou N. L., Papadimitriou N., Gill D., Christakoudi S., Murphy N., Gunter M. J., Travis R.C., Key T. J., Fortner R.T., Haycock P.C., Lewis S.J., Muir K., Martin R.M., Tsilidis K.K. Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, Vol. 48, no. 3, pp. 807-816. [doi: 10.1093/ije/dyz107]
  11. Gammon M.D., Sagiv S.K., Eng S.M., Shantakumar S., Gaudet M.M., Teitelbaum S.L., Britton J.A., Terry M.B., Wang L.W., Wang Q., Stellman S.D., Beyea J., Hatch M., Kabat G.C., Wolff M.S., Levin B., Neugut A.I., Santella R.M. Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: a pooled analysis. Arch. Environ. Health, 2004, Vol. 59, no. 12, pp. 640-649. [doi: 10.1080/00039890409602948]
  12. James R.E., Lukanova A., Dossus L., Becker S., Rinaldi S., Tjønneland A., Olsen A., Overvad K., Mesrine S., Engel P., Clavel-Chapelon F., Chang-Claude J., Vrieling A., Boeing H., Schütze M., Trichopoulou A., Lagiou P., Trichopoulos D., Palli D., Krogh V., Panico S., Tumino R., Sacerdote C., Rodríguez L., Buckland G., Sánchez M.J., Amiano P., Ardanaz E., Bueno-de-Mesquita B., Ros M.M., van Gils C.H., Peeters P.H., Khaw K.T., Wareham N., Key T.J., Allen N.E., Romieu I., Siddiq A., Cox D., Riboli E., Kaaks R. Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study. Cancer Prev. Res. (Phila), 2011, Vol. 4, no. 10, pp. 1626-35. [doi: 10.1158/1940-6207.CAPR-11-0090]
  13. Kim J.Y., Han W., Moon H.G., Ahn S.K., Kim J., Lee J.W., Kim M.K., Kim T., Noh D.Y. Prognostic effect of preoperative serum estradiol level in postmenopausal breast cancer. BMC Cancer, 2013 Vol. 13, pp. 503. [doi: 10.1186/1471-2407-13-503]
  14. Li Z., Wei H., Li S., Wu P., Mao X. The Role of Progesterone Receptors in Breast Cancer. Drug Des., Devel. Ther., 2022, Vol. 16, pp. 305-314. [doi: 10.2147/DDDT.S336643]
  15. Mohammed H., Russell I.A., Stark R., Rueda O.M., Hickey T.E., Tarulli G.A., Serandour A.A., Birrell S.N., Bruna A., Saadi A., Menon S., Hadfield J., Pugh M., Raj G.V., Brown G.D., D'Santos C., Robinson J.L., Silva G., Launchbury R., Perou C.M., Stingl J., Caldas C., Tilley W.D., Carroll J.S. Progesterone receptor modulates ERα action in breast cancer. Nature, 2015, Vol. 523, no. 7560, pp. 313-317. [doi: 10.1038/nature14583]
  16. Nielsen T.O, Leung S.C.Y., Rimm D.L., Dodson A., Acs B., Badve S., Denkert C., Ellis M.J., Fineberg S., Flowers M., Kreipe H.H., Laenkholm A.V., Pan H., Penault-Llorca F.M., Polley M.Y., Salgado R., Smith I.E, Sugie T., Bartlett J.M.S., McShane L.M., Dowsett M., Hayes D.F. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst., 2021, Vol. 113, no. 7, pp. 808-819. [doi: 10.1093/jnci/djaa201]
  17. Pruthi S., Yang L., Sandhu N.P., Ingle J.N., Beseler C.L., Suman V.J., Cavalieri E.L., Rogan E.G. Evaluation of serum estrogen-DNA adducts as potential biomarkers for breast cancer risk. J. Steroid Biochem. Mol. Biol., 2012, Vol. 132, no. 1-2, pp. 73-79. [doi: 10.1016/j.jsbmb.2012.02.002]
  18. Sagiv S.K., Gaudet M.M., Eng S.M., Abrahamson P.E., Shantakumar S., Teitelbaum S.L., Bell P., Thomas J.A., Neugut A.I., Santella R.M., Gammon M.D. Polycyclic aromatic hydrocarbon-DNA adducts and survival among women with breast cancer. Environ. Res., 2009, Vol. 109, no. 3, pp. 287-291. [doi: 10.1016/j.envres.2008.11.005]
  19. Tin Tin S., Reeves G.K., Key T.J. Endogenous hormones and risk of invasive breast cancer in pre- and post-menopausal women: findings from the UK Biobank. Br. J. Cancer, 2021, Vol. 125, no. 1, pp. 126-134. [doi: 10.1038/s41416-021-01392-z]
  20. Yang L., Zahid M., Liao Y., Rogan E.G., Cavalieri E.L., Davidson N.E., Yager J.D., Visvanathan K., Groopman J.D., Kensler T.W. Reduced formation of depurinating estrogen–DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. Reduced formation of depurinating estrogen-DNA adducts by sulforaphane or KEAP1 disruption in human mammary epithelial MCF-10A cells. Carcinogenesis, 2013, Vol. 34, no. 11, pp. 2587-2592. [doi: 10.1093/carcin/bgt246]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) Polenok E.G., Gordeeva L.A., Kostyanko M.V., Zakharov V.N., Antonov A.V., Bairamov P.V., Verzhbitskaja N.E., Kolpinskiy G.I., Glushkov A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies